Pharmacogenomics Basics - Gene-Drug Dance
- Definition: Study of how an individual’s genetic makeup influences their response to drugs. Aims for personalized medicine: maximizing efficacy, minimizing toxicity.
- Core Principle: Genetic variations (e.g., Single Nucleotide Polymorphisms - SNPs, Copy Number Variations - CNVs) in genes coding for:
- Drug-metabolizing enzymes (e.g., Cytochrome P450 family like CYP2D6, CYP2C19)
- Drug transporters (e.g., SLCO1B1)
- Drug targets (e.g., VKORC1 for warfarin)
- Impacts: Primarily Pharmacokinetics (PK - what the body does to the drug, especially metabolism) and Pharmacodynamics (PD - what the drug does to the body).
- Resulting Phenotypes (examples for metabolizing enzymes):
- Poor Metabolizers (PM): ↓ enzyme activity → ↑ drug levels, ↑ risk of toxicity.
- Ultrarapid Metabolizers (UM): ↑ enzyme activity → ↓ drug levels, risk of therapeutic failure.
- Extensive Metabolizers (EM): Normal enzyme activity.
- Intermediate Metabolizers (IM): Between PM and EM.
⭐ Over 200 drugs now have pharmacogenomic information in their FDA-approved labeling, highlighting its growing clinical importance.
Key Pharmacogenes - Enzyme & Transporter Tales
| Gene (Product) | Key Drug(s) | Variant Implication | Note/Mnemonic |
|---|---|---|---|
| CYP2D6 (Enzyme) | Codeine, Tamoxifen | PMs: ↓ efficacy/ADRs (Codeine: ↓ analgesia). UMs: ↑ toxicity. | 📌 2D6: Diverse Drugs, 6 phenotypes |
| CYP2C9 (Enzyme) | Warfarin, Phenytoin | ↓ activity (*2,*3): ↑ Warfarin levels, bleeding risk. Dose ↓. | |
| CYP2C19 (Enzyme) | Clopidogrel, PPIs | PMs (*2,*3): ↓ Clopidogrel activation → risk CV events. UMs (*17): ↑ bleeding. | 📌 Clopi-2C19: Cardiac Concern |
| TPMT (Enzyme) | Azathioprine, 6-MP | ↓ activity: ↑ TGNs → myelosuppression. Test before. | |
| UGT1A1 (Enzyme) | Irinotecan | *28 (Gilbert's): ↓ SN-38 glucuronidation → ↑ toxicity (diarrhea, neutropenia). | |
| SLCO1B1 (OATP1B1) | Statins (Simvastatin) | c.521T>C: ↓ statin uptake → ↑ plasma levels → myopathy risk. | 📌 SLCO: Statin Level Control |
| VKORC1 (Enzyme target) | Warfarin | Variants: affect warfarin sensitivity. Dose adjustment. | Warfarin's target |
| DPYD (Enzyme) | 5-FU, Capecitabine | Deficiency: ↓ catabolism → severe toxicity. | |
| HLA-B*57:01 (MHC) | Abacavir | AHS risk. Mandatory screening. | ⭐ > HLA-B*57:01 screening for abacavir prevents severe hypersensitivity. |
| HLA-B*15:02 (MHC) | Carbamazepine | SJS/TEN risk (Asians). Test before. |
Clinical Applications - Prescribing Pointers
Pharmacogenomics guides personalized drug therapy, optimizing efficacy and minimizing adverse drug reactions (ADRs). Key clinical examples:
- Warfarin: CYP2C9, VKORC1 variants.
- Altered metabolism/sensitivity.
- Requires dose adjustments to prevent bleeding/clotting.
- Clopidogrel: CYP2C19 loss-of-function alleles.
- Prodrug; poor metabolizers (PMs) have ↓ activation, ↑ risk of stent thrombosis.
- Consider alternatives (prasugrel, ticagrelor) in PMs.
- Abacavir (HIV): HLA-B*57:01 allele.
- Strong association with abacavir hypersensitivity (AHR).
- Screening mandatory; contraindicated if positive.
- Azathioprine/6-MP: TPMT, NUDT15 variants.
- ↓ enzyme activity → ↑ drug levels.
- High risk of severe myelosuppression. Dose reduction needed.
- Carbamazepine: HLA-B*15:02 (Asians), HLA-A*31:01 (Europeans).
- Risk of SJS/TEN. Screening recommended in specific populations.
- Codeine: CYP2D6 polymorphisms.
- Ultra-rapid metabolizers (UMs): risk of toxicity.
- Poor metabolizers (PMs): ↓ analgesia.
- Irinotecan: UGT1A1*28 (Gilbert's).
- ↓ activity → ↑ SN-38. Risk of neutropenia, diarrhea. Dose reduction.
⭐ HLA-B*57:01 testing before abacavir initiation has dramatically reduced the incidence of hypersensitivity reactions, making it a cornerstone of HIV therapy safety.
High‑Yield Points - ⚡ Biggest Takeaways
- CYP2D6 polymorphisms impact codeine metabolism; poor metabolizers (PMs) have ↓ efficacy, ultra-rapid metabolizers (UMs) risk toxicity.
- CYP2C19 variants affect clopidogrel activation; PMs have ↑ risk of stent thrombosis.
- TPMT/NUDT15 deficiency causes severe toxicity with thiopurines (azathioprine, 6-MP).
- HLA-B*5701 screening is crucial before abacavir to prevent hypersensitivity.
- Warfarin dosing is guided by CYP2C9 and VKORC1 genotypes.
- SLCO1B1 variants increase risk of statin-induced myopathy.
- G6PD deficiency predisposes to drug-induced hemolytic anemia (e.g., primaquine).
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app
